Skip to main content
. 2024 Mar 18;11(3):617–632. doi: 10.1007/s40744-024-00654-5

Fig. 3.

Fig. 3

Change from baseline over time in HAQ-DI. Reported using MMRM. CI confidence interval, HAQ-DI Health Assessment Questionnaire–Disability Index, MMRM mixed-effect model for repeated measures, PBO placebo, RZB risankizumab